Connect with us


Theresa May Calls General Election on June 8th



Theresa May has today called for a early General Election to take place on June 8th 2017 pending parliamentary approval tomorrow.

In a surprise announcement Prime Minister Theresa May has called for a early ‘snap’ general election and will apply to parliament tomorrow for approval.

Tomorrows parliamentary vote will allow the government to override the Fixed-term Parliaments Act of 2011 and allow a snap election. May will need a 2/3 majority vote to formally schedule the election.

The election will take place on June 8th 2017.

May cited Brexit as the primary reason for the early election saying that “there should be unity here in Westminster, but instead there is division. The country is coming together, but Westminster is not”.

She went on to explain that is it only “recently and reluctantly” she realised a general election is on the only way forward after previously ruling an early election out when questioned.

In her statement May claimed that ongoing criticism from across all political parties means she is unable to secure the best Brexit deal with Labour saying they will “vote against the deal”, Liberal Democrats “wanting to grind the business of government to a standstill” and The Scottish National Party saying “they will vote against the legislation that formally repeals Britain’s membership of the European Union”.

YouGov currently has consistently put the Conservative Party ahead in all opinion polls for quite some time and with all other parties significantly behind.

Ongoing disputes over pay restraint put Nurses and other healthcare workers in a powerful voting position and will now start to seek the support of political parties over the issue in an attempt to influence voters. We have approached the RCN for Unison for comment.

Continue Reading
Join the discussion...

Leave a Reply

Your email address will not be published. Required fields are marked *


Royal College of Midwives to end campaign to promote ‘normal births’




The Royal College of Midwives ends their campaign for “normal births” to avoid making mothers who opt for medical interventions feel like failures.

The Royal College of Midwives (RCM) has been running a continuous campaign since 2005 to encourage expectant mothers to give birth without medical interventions such as; epidurals, inductions and caesareans.

Currently, around 40% of mothers give birth without medical interventions. 20% less than 30 years ago. But experts say a significant number of these are due to the increase in more risky pregnancies.

Prof Cathy Warwick, the Chief Executive of the RCM, said;

“There was a danger that if you just talk about normal births – and particularly if you call it a campaign – it kind of sounds as if you’re only interested in women who have a vaginal birth without intervention”.

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately, that seems to be how some women feel.”

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately that seems to be how some women feel.”

Midwives, will instead, start to use the term “physiological births” to describe those without interventions.

Continue Reading


Pancreatic cancer patients to have routine access to life extending drug after new deal



NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and provided more evidence on its effectiveness.

Nab-paclitaxel, also known as Abraxane, made by Celgene will be routinely available as an option for patients with pancreatic cancer that has progressed.

When Abraxane is added to a standard chemotherapy, called gemcibatine the evidence has found it extends life by an average of 2.4 months.

If other combination chemotherapy treatments are unsuitable for a patient, NICE recommends offering Abraxane instead of this standard chemotherapy on its own.

It works by blocking the action of the proteins within cancer cells that cause them to grow and divide.

NICE has reviewed its guidance from 2015 which did not recommend Abraxane for routine NHS use for not being cost-effective.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: The life expectancy of pancreatic cancer is poor, with patients usually living for only up to 6 months. It’s incredibly important that patients and families affected by this disease are able to have routine access to this life extending treatment.”

There are almost 10,000 new cases of pancreatic cancer each year in the UK, and less than 1% survive for 10 or more years.

This is a final appraisal determination for Abraxane. The company, healthcare professionals and patient/carer organisations now have until Friday 1 September to appeal the decision.

Continue Reading